Research programme: recombinant human acid ceramidase - Plexcera Therapeutics

Drug Profile

Research programme: recombinant human acid ceramidase - Plexcera Therapeutics

Alternative Names: Recombinant human acid ceramidase; rhAC; RVT-801

Latest Information Update: 18 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Icahn School of Medicine at Mount Sinai
  • Developer Enzyvant Sciences; Plexcera Therapeutics
  • Class Ceramidases
  • Mechanism of Action Acid ceramidase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Farber lipogranulomatosis
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Farber lipogranulomatosis
  • Discontinued Cystic fibrosis

Most Recent Events

  • 16 Oct 2017 Recombinant human acid ceramidase receives Orphan Drug status for Farber lipogranulomatosis in European Union before October 2017
  • 16 Oct 2017 Enzyvant plans a clinical trial for Farber lipogranulomatosis in 2018
  • 02 Aug 2016 Discontinued - Preclinical for Cystic fibrosis in USA (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top